감염증용 진단 시약 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 질환 영역별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Diagnostic Reagents For Infectious Diseases Market Summary

The global diagnostic reagents for infectious diseases market size was estimated at USD 3,475.31 millionin 2024 and is projected to reach USD 8,079.07 million by 2033, growing at a CAGR of 9.30% from 2025 to 2033. The market is primarily driven by the increasing prevalence of respiratory diseases and sexually transmitted infections (STIs).

Respiratory diseases, including influenza, COVID-19, pneumonia, and tuberculosis, have the highest prevalence worldwide. The UNICEF 2023 report stated that, every year, there are over 1,400 cases of pneumonia per 100,000 children worldwide, or one case per 71 children, with the highest incidences occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000) in 2023.

Moreover, the WHO estimated 10.8 million people worldwide became ill with tuberculosis, including 6.0 million men, 3.6 million women, and 1.3 million. Therefore, the rising prevalence rate is driving strong demand for advanced diagnostic technologies such as molecular diagnostics and point-of-care testing, fueling market growth. In addition, the rapid expansion of telemedicine services and the growing adoption of home-based testing solutions are further contributing to the market's expansion.

Furthermore, rising global awareness and government-supported screening programs are encouraging early detection and prevention initiatives. The Journal of Global Health reported in May 2025 that the distribution and health impact of infectious disease outbreaks from 1996 to 2023 were globally assessed. The World Health Organization has identified approximately 30 priority pathogens, including monkeypox virus, dengue virus, and influenza A viruses, that could cause global public health emergencies. This updated list emphasizes the significance of focusing efforts on these high-risk infections due to their high transmissibility, virulence, and the scarcity of vaccines and treatment options. As global concerns such as climate change, deforestation, and growing urbanization increase the risk of these illnesses spreading, boosting the demand for infectious disease reagents.

Furthermore, the expansion of advanced molecular technologies in developing regions is playing a crucial role in driving market growth. Growing investments in healthcare infrastructure and increasing access to innovative diagnostic tools are enabling faster, cost-effective, and more accurate detection of infectious diseases. For instance, in January 2024, QIAGEN (Netherlands) launched testing panels for its QIAstat-Dx instruments, along with reagents, in India for rapid and accurate diagnosis of infectious diseases. Such initiatives are accelerating the adoption of molecular diagnostics in developing regions and significantly contributing to market growth.

Moreover, the increasing funding by governments to target pathogen genomic surveillance is boosting the demand for infectious disease reagents associated with molecular diagnostics. In February 2024, the WHO announced that donors had contributed USD 4 million to establish a catalytic grant fund for organizations working in pathogen genomic surveillance. The fund will support pilot projects worldwide, particularly in low- and middle-income countries. As laboratories implement these pilot projects, there is an increased need for molecular diagnostics reagents, including PCR kits, sequencing reagents, and other consumables. This expansion of testing capabilities ensures more frequent and routine use of reagents, creating sustained demand while enhancing global capacity to detect, prevent, and respond effectively to infectious disease outbreaks.

Global Diagnostic Reagents For Infectious Diseases Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global diagnostic reagents for infectious diseases market report based on product, disease area, technology, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Reagents
• Immunoassay Reagents
• Rapid Test Reagents
• Serology Reagents
• Controls and Calibrators
• Other Reagents
• Disease Area Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory Infections
• Vector-Borne & Tropical Diseases
• Enteric Infections
• Sexually Transmitted Infections (STIs)
• Other Emerging / High-Burden Infectious Diseases
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Diagnostics
• Immunoassays
• Point-of-Care Reagents
• Multiplex Platforms
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Point-of-Care / Decentralized Testing Sites
• Public Health Agencies & National Reference Labs
• Academic & Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Diagnostic Reagents for Infectious Diseases Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product
    • 1.1.1.2. Disease Area Segment
    • 1.1.1.3. Technology Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Diagnostic Reagents for Infectious Diseases Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product
• 2.3. Disease Area Snapshot
• 2.4. Technology Snapshot
• 2.5. End Use Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. Diagnostic Reagents for Infectious Diseases Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Increase in re-emerging infectious diseases
  • 3.4.2. Advancements in molecular diagnostics
• 3.5. Market Restraint Analysis
  • 3.5.1. Complex validation processes
  • 3.5.2. High cost of infectious disease diagnostic reagents
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Diagnostic Reagents for Infectious Diseases Market: Product Estimates & Trend Analysis

• 4.1. Diagnostic Reagents for Infectious Diseases Market: Product Movement Analysis
• 4.2. Molecular Reagents
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Immunoassay Reagents
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Rapid Test Reagents
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Serology Reagents
  • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Controls and Calibrators
  • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Other Reagents
  • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Diagnostic Reagents for Infectious Diseases Market: Disease Area Estimates & Trend Analysis

• 5.1. Diagnostic Reagents for Infectious Diseases Market: Disease Area Movement Analysis
• 5.2. Respiratory Infections
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Vector-Borne & Tropical Diseases
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Enteric Infections
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Sexually Transmitted Infections (STIs)
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Other Emerging / High-Burden Infectious Diseases
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Diagnostic Reagents for Infectious Diseases Market: Technology Estimates & Trend Analysis

• 6.1. Diagnostic Reagents for Infectious Diseases Market: End Use Movement Analysis
• 6.2. Molecular Diagnostics
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Immunoassays
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Point-of-Care Reagents
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Multiplex Platforms
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Diagnostic Reagents for Infectious Diseases Market: End Use Estimates & Trend Analysis

• 7.1. Diagnostic Reagents for Infectious Diseases Market: End Use Movement Analysis
• 7.2. Hospitals & Clinics
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Diagnostic Laboratories
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Point-of-Care / Decentralized Testing Sites
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Public Health Agencies & National Reference Labs
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Diagnostic Reagents for Infectious Diseases Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Diagnostic Reagents for Infectious Diseases Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germany
    • 8.3.3.1. Germany Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia-Pacific Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario

. Competitive Scenario

• 8.5. Latin America
  • 8.5.1. Latin America Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Diagnostic Reagents for Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. New Product Launch
  • 9.2.2. Partnerships
  • 9.2.3. Acquisition
  • 9.2.4. Collaboration
  • 9.2.5. Funding
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. F. Hoffmann-La Roche Ltd
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Abbott
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. QIAGEN
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. bioMerieux
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Bio-Rad Laboratories, Inc.
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Seegene Inc.
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Thermo Fisher Scientific, Inc.
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. SD Biosensor
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Mindray
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Boditech Med Inc.
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives